Anti-CD38 therapy for PLA2R-positive membranous nephropathy resistant to conventional immunosuppression

Kidney Int. 2022 Feb;101(2):416-418. doi: 10.1016/j.kint.2021.11.001.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Glomerulonephritis, Membranous* / drug therapy
  • Humans
  • Immunosuppression Therapy
  • Receptors, Phospholipase A2

Substances

  • Receptors, Phospholipase A2